Menu

National Cancer Institute Will Stop Funding Nanotechnology Centers

The Centers of Cancer Nanotechnology Excellence were established in 2005 through several phases of funding, which are reported to end next year.

May 20, 2019
Chia-Yi Hou

ABOVE: National Cancer Institute in Maryland
NATIONAL CANCER INSTITUTE

The US National Cancer Institute announced that next year it will stop funding the Centers of Cancer Nanotechnology Excellence, reports Science. The Centers encompasses several research groups at various institutions, including Caltech, the University of California, Los Angeles, Northwestern University, Cornell University, and others, according to its website.

The Centers of Cancer Nanotechnology Excellence (CCNEs) focus on developing nanotechnology for cancer treatment. The end to funding represents a “natural transition” from putting dedicated support into an emerging field to becoming a more mature research field that fits in with other cancer fields, says Piotr Grodzinski of the National Cancer Institute’s (NCI) Nanodelivery Systems and Devices Branch, which oversees the CCNEs, to Science.

The CCNEs started in 2005 as eight research groups in the first phase, nine getting funding in 2010 in the second phase, and six funded in 2015 for the third phase, according to Science. Some experts state that ceasing their funding may negatively affect cancer research and the future possibility for using nanotechnology in treatments because it unlinks the two fields. “You might not see the integration between disciplines,” Michelle Bradbury, a radiologist at Memorial Sloan Kettering Cancer Center where one of the CCNEs is based, tells Science.

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.